ArticleJournal of controlled release : official journal of the Controlled Release Society2005
Enhanced antigen presentation and immunostimulation of dendritic cells using acid-degradable cationic nanoparticles.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 147 citations in OpenAlex.
- Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves.BMC veterinary research · 2015Trial
- Co-Delivery of a Novel Lipidated TLR7/8 Agonist and Hemagglutinin-Based Influenza Antigen Using Silica Nanoparticles Promotes Enhanced Immune Responses.Pharmaceutics · 2024Article
- Systematic identification of gene combinations to target in innate immune cells to enhance T cell activation.Nature communications · 2023Article
- An antigen self-assembled and dendritic cell-targeted nanovaccine for enhanced immunity against cancer.Acta pharmaceutica Sinica. B · 2023Article
- Nanomaterials-Based Novel Immune Strategies in Clinical Translation for Cancer Therapy.Molecules (Basel, Switzerland) · 2023Review
- Protein-based antigen presentation platforms for nanoparticle vaccines.NPJ vaccines · 2021Review
- Considerations for Size, Surface Charge, Polymer Degradation, Co-Delivery, and Manufacturability in the Development of Polymeric Particle Vaccines for Infectious Diseases.Advanced nanobiomed research · 2021Article
- In Vitro Characterization of Inhalable Cationic Hybrid Nanoparticles as Potential Vaccine Carriers.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Integrated System for Purification and Assembly of PCV Cap Nano Vaccine Based on Targeting Peptide Ligand.International journal of nanomedicine · 2020Article
- Ultrasound-guided immunofunctional photoacoustic imaging for diagnosis of lymph node metastases.Nanoscale · 2019Article
- Effects of engineered nanoparticles on the innate immune system.Seminars in immunology · 2017Review
- Tolerogenic Nanoparticles to Treat Islet Autoimmunity.Current diabetes reports · 2017Review
- Micro and Nano Material Carriers for Immunomodulation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2016Review
- Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2015Review
- Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease.Vaccines · 2015Article
- Article
- Nanogels from metal-chelating crosslinkers as versatile platforms applied to copper-64 PET imaging of tumors and metastases.Theranostics · 2015Article
- Toll-like receptor 6 mediated inflammatory and functional responses of zinc oxide nanoparticles primed macrophages.Immunology · 2014Article
- Metal Chelating Crosslinkers Form Nanogels with High Chelation Stability.Journal of materials chemistry. B · 2013Article
- Multifunctional nanorods serving as nanobridges to modulate T cell-mediated immunity.ACS nano · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Acid-degradable cationic nanoparticles encapsulating a model antigen (i.e., ovalbumin) were prepared by inverse microemulsion polymerization with acid-cleavable acetal cross-linkers. Incubation of these degradable nanoparticles with dendritic cells derived from bone marrow (BMDCs) resulted in the enhanced presentation of ovalbumin-derived peptides, as quantified by B3Z cells, a CD8+ T cell hybridoma. The cationic nature of the particles contributed to the increased surface endocytosis (or phagocytosis) observed with BMDCs, which is the first barrier to overcome for successful antigen delivery. The acid sensitivity of the particles served to direct more ovalbumin antigens to be processed into the appropriately trimmed peptide fragments and presented via the major histocompatibility complex (MHC) class I pathway following hydrolysis within the acidic lysosomes. It was also shown that adjuvant molecules such as unmethylated CpG oligonucleotides (CpG ODN) and anti-interleukin-10 oligonucleotides (AS10 ODN) could be co-delivered with the protein antigen for maximized cellular immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.